Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2017 06:00 ET | Source: pSivida Corp.

pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution

NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th, at 8:30 a.m. ET ...
October 18, 2017 07:00 ET | Source: pSivida Corp.

pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...
October 10, 2017 07:00 ET | Source: pSivida Corp

pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma

WATERTOWN, Mass. and SOPHIA ANTIPOLIS, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and...
September 26, 2017 07:00 ET | Source: pSivida Corp

pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs

WATERTOWN, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement...
September 22, 2017 14:28 ET | Source: pSivida Corp

pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference

WATERTOWN, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that...
September 11, 2017 16:01 ET | Source: pSivida Corp

pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results

Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 11, 2017 ...
September 11, 2017 07:00 ET | Source: pSivida Corp

pSivida to Present at Rodman & Renshaw Annual Global Investment Conference

WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that...
September 05, 2017 07:00 ET | Source: pSivida Corp

pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th

WATERTOWN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...
August 01, 2017 07:00 ET | Source: pSivida Corp

pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017

WATERTOWN, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases,...
July 18, 2017 07:00 ET | Source: pSivida Corp

Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences

WATERTOWN, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three...